Table 1:
Adult and pediatric CMV seroprevalence among blood donors, organ donors, and recipients by age and sex
| Blood donors | Organ donors | Recipients | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | n | Prevalence, % (95% CI) | POR (95% CI) | n | Prevalence, % (95% CI) | POR (95% CI) | n | Prevalence, % (95% CI) | POR (95% CI) | |
| Overall adult prevalence | 1,253,350 (25, 15) | 42.2bc (42.1 to 42.3) | — | 2,588* (42.6, 23.0) | 53.3ab (51.4 to 55.3) | — | 4,113* (50.9, 19.2) | 62.3ac (60.8 to 63.8) | — | |
| Adult age group | ||||||||||
| 17–29 y | 499,529 | 33.8bc (33.7 to 33.9) | 1.00 (Ref.) | 658 | 43.0ab (39.2 to 46.9) | 1.00 (Ref.) | 445 | 48.3ac (43.6 to 53.1) | 1.00 (Ref.) | |
| 30–39 y | 218,959 | 42.4ab (42.2 to 42.6) | 1.44 (1.43 to 1.46) | 475 | 50.9a (46.4 to 55.5) | 1.38 (1.08 to 1.75) | 599 | 49.6b (45.5 to 53.7) | 1.05 (0.82 to 1.34) | |
| 40–49 y | 264,977 | 46.4bc (46.2 to 46.6) | 1.70 (1.68 to 1.71) | 626 | 55.8ab (51.8 to 59.7) | 1.67 (1.34 to 2.08) | 916 | 59.4ac (56.1 to 62.6) | 1.56 (1.25 to 1.97) | |
| 50–59 y | 205,037 | 51.4bc (51.2 to 51.7) | 2.08 (2.05 to 2.10) | 535 | 57.0ab (52.7 to 61.2) | 1.76 (1.40 to 2.21) | 1,249 | 68.0ac (65.3 to 70.6) | 2.27 (1.82 to 2.83) | |
| 60–69 y | 63,520 | 59.1bc (58.9 to 59.5) | 2.84 (2.79 to 2.89) | 193 | 65.8ab (58.6 to 72.4) | 2.55 (1.83 to 3.58) | 819 | 72.9ac (69.7 to 75.9) | 2.88 (2.26 to 3.67) | |
| >70 y | 1,328 | 66.7 (64.1 to 69.2) | 3.93 (3.51 to 4.41) | 101 | 73.3 (63.5 to 81.5) | 3.63 (2.30 to 5.88) | 85 | 69.4 (58.5 to 79.0) | 2.43 (1.49 to 4.05) | |
| Adult sex | ||||||||||
| Male | 590,675 | 40.8 (40.7 to 40.9) | 1 (Ref.) | 1,308 | 47.7 (45.0 to 50.5) | 1.00 (Ref.) | 2,712 | 59.4 (57.5 to 61.2) | 1.00 (Ref.) | |
| Female | 662,675 | 43.4bc (43.3 to 43.5) | 1.11 (1.10 to 1.12) | 1,280 | 59.1ab (56.3 to 61.8) | 1.58 (1.35 to 1.85) | 1,401 | 67.9ac (65.4 to 70.3) | 1.45 (1.26 to 1.66) | |
| Overall pediatric prevalence for those aged <12 mo | — | — | — | 250* (10.7, 10.5) | 44.4 (38.1 to 50.8) | — | 302* (8.1, 10.1) | 44.4 (38.7 to 50.2) | — | |
| Pediatric age group | <12 mo | — | — | — | 52 | 44.2 (30.5 to 58.7) | — | 112 | 50.0 (40.4 to 59.6) | — |
| 12 mo–2 y | — | — | — | 24 | 29.2 (12.6 to 51.1) | 1.00 (Ref.) | 50 | 34.0 (21.2 to 48.8) | 1.00 (Ref.) | |
| 2–4 y | — | — | — | 42 | 47.6 (32.0 to 63.6) | 2.21 (0.78 to 6.74) | 53 | 45.3 (31.6 to 59.6) | 1.61 (0.73 to 3.60) | |
| 5–9 y | — | — | — | 52 | 38.5 (25.3 to 53.0) | 1.52 (0.55 to 4.52) | 65 | 43.1 (30.8 to 56.0) | 1.47 (0.69 to 3.19) | |
| 10–16 y | — | — | — | 132 | 48.5 (39.7 to 57.3) | 2.29 (0.92 to 6.25) | 134 | 48.5 (39.8 to 57.3) | 1.83 (0.94 to 3.66) | |
| Pediatric sex | ||||||||||
| Male | — | — | — | 147 | 40.8 (32.8 to 49.2) | 1.00 (Ref.) | 148 | 37.8 (30.0 to 46.2) | 1.00 (Ref.) | |
| Female | — | — | — | 103 | 49.5 (39.5 to 59.5) | 1.42 (0.86 to 2.37) | 154 | 50.6 (42.5 to 58.8) | 1.69 (1.07 to 2.67) | |
Notes: Pediatric patients aged younger than 12 mo are included in the table to describe the seroprevalence of this group, but they were excluded from the regression analysis because of the potential presence of passive maternal antibody. Superscript letters indicate statistically significant pairwise comparisons with adjusted p < 0.05. Boldface indicates significant at α = 0.05. Dashes indicate not applicable.
* Exclusions due to missing or indeterminate serology: 35 adult donors (32 indeterminate), 75 adult recipients (49 indeterminate), 8 pediatric donors (8 indeterminate), and 6 pediatric recipients (4 indeterminate)
CMV = Cytomegalovirus; IQR = Interquartile range; CI = Confidence interval; POR = Prevalence odds ratio; Ref. = reference